Insider transactions

Mitchell S Levine

CIK 1383492 · Chief Financial Officer · last filed 2022-03-17

Mitchell S Levine is a Chief Financial Officer who has filed 32 SEC Form 4 insider transactions across 1 company since 2017. The most recent filing, for OCX, was dated Mar 17, 2022. Across all open-market trades the lifetime net is +$102.5K, making them a net buyer over the disclosed history. 40 SEC filings were submitted jointly with Enable Capital Management, LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$0
Companies
1
Total Filings
32
Lifetime Open-Market Net
$102.5K

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address
ONE FERRY BUILDING, SUITE 255
SAN FRANCISCO, CA 94111
Related Filers
Enable Capital Management, LLC — 40 joint filings, latest 2011-05-17
Enable Growth Partners L P — 40 joint filings, latest 2011-05-17
Enable Opportunity Partners L P — 40 joint filings, latest 2011-05-17
Pierce Diversified Strategy Master Fund, LLC — 38 joint filings, latest 2010-01-12
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Insight Molecular Diagnostics Inc. (OCX) Delisted Chief Financial Officer 4,354 $3.20 $13.9K $102.5K 18 2022-03-17

Recent Filings

32 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-03-17 Insight Molecular Diagnostics Inc. (OCX) Delisted Grant (A) — $0 EDGAR
2022-03-15 Insight Molecular Diagnostics Inc. (OCX) Delisted Buy (P) +25,000 $29.1K EDGAR
2021-04-30 Insight Molecular Diagnostics Inc. (OCX) Delisted Mixed +15,380 $0 EDGAR
2021-03-01 Insight Molecular Diagnostics Inc. (OCX) Delisted Grant (A) — $0 EDGAR
2020-12-17 Insight Molecular Diagnostics Inc. (OCX) Delisted Buy (P) +10,000 $20.1K EDGAR
2020-12-15 Insight Molecular Diagnostics Inc. (OCX) Delisted Grant (A) +10,121 $0 EDGAR
2020-12-15 Insight Molecular Diagnostics Inc. (OCX) Delisted Buy (P) +10,000 $20.1K EDGAR
2020-08-04 Insight Molecular Diagnostics Inc. (OCX) Delisted Buy (P) +10,000 $13.2K EDGAR
2020-04-30 Insight Molecular Diagnostics Inc. (OCX) Delisted Grant (A) — $0 EDGAR
2020-04-30 Insight Molecular Diagnostics Inc. (OCX) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 32
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.